A study of NBI-74788 for the treatment of classic congenital adrenal hyperplasia (CAH).
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2017
At a glance
- Drugs NBI 74788 (Primary)
- Indications Congenital adrenal hyperplasia
- Focus Adverse reactions; Pharmacokinetics
- 01 Nov 2017 Status changed from recruiting to completed, according to a Neurocrine Biosciences media release.
- 09 May 2017 Status changed from planning to recruiting, according to a Neurocrine Biosciences media release.
- 17 Feb 2017 According to a Neurocrine Biosciences media release, the company plans to initiate this study in 2017.